J
Jørgen K. Kanters
Researcher at University of Copenhagen
Publications - 232
Citations - 5502
Jørgen K. Kanters is an academic researcher from University of Copenhagen. The author has contributed to research in topics: QT interval & Long QT syndrome. The author has an hindex of 35, co-authored 206 publications receiving 4664 citations. Previous affiliations of Jørgen K. Kanters include Aalborg Hospital & Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
The genetic basis of long QT and short QT syndromes: a mutation update.
Paula L. Hedley,Paula L. Hedley,Poul Jørgensen,Poul Jørgensen,Sarah Schlamowitz,Romilda Wangari,Johanna C. Moolman-Smook,Paul A. Brink,Jørgen K. Kanters,Valerie A. Corfield,Michael Christiansen +10 more
TL;DR: The present mutation update is a comprehensive description of all known LQTS‐ and SQTS‐associated mutations.
Journal ArticleDOI
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome.
Eva Delpón,Jonathan M. Cordeiro,Lucía Núñez,Poul Erik Bloch Thomsen,Alejandra Guerchicoff,Guido D. Pollevick,Yuesheng Wu,Jørgen K. Kanters,Carsten Toftager Larsen,Jacob Hofman-Bang,Elena Burashnikov,Michael Christiansen,Charles Antzelevitch +12 more
TL;DR: These results provide definitive evidence for a functional role of KCNE3 in the modulation of Ito in the human heart and suggest that mutations in KC NE3 can underlie the development of the Brugada syndrome.
Journal ArticleDOI
Automatic Selection of the Threshold Value $r$ for Approximate Entropy
TL;DR: This work derives general equations that can be used to estimate the maximum ApEn with high accuracy for a given value of m, and derives a heuristic stochastic model based on Monte Carlo simulations that overcomes this computational burden and leads to the automatic selection of themaximum ApEn value for any given signal.
Journal ArticleDOI
Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events: Implications for Mutation-Specific Response to Beta-Blocker Therapy in Type-1 Long QT Syndrome
Alon Barsheshet,Ilan Goldenberg,Jin O-Uchi,Arthur J. Moss,Christian Jons,Wataru Shimizu,Arthur A.M. Wilde,Scott McNitt,Derick R. Peterson,Wojciech Zareba,Jennifer L. Robinson,Michael J. Ackerman,Michael W. Cypress,Daniel A. Gray,Nynke Hofman,Jørgen K. Kanters,Elizabeth S. Kaufman,Pyotr G. Platonov,Ming Qi,Jeffrey A. Towbin,G. Michael Vincent,Coeli M. Lopes +21 more
TL;DR: Reduced channel activation after sympathetic activation can explain the increased clinical risk and response to therapy in patients with C-loop mutations and derive a pronounced benefit from treatment with &bgr;-blockers.
Journal ArticleDOI
The genetic basis of Brugada syndrome: a mutation update.
Paula L. Hedley,Paula L. Hedley,Poul Jørgensen,Poul Jørgensen,Sarah Schlamowitz,Johanna C. Moolman-Smook,Jørgen K. Kanters,Valerie A. Corfield,Michael Christiansen +8 more
TL;DR: BrS exhibits variable expressivity, reduced penetrance, and “mixed phenotypes,” where families contain members with BrS as well as long QT syndrome, atrial fibrillation, short QT Syndrome, conduction disease, or structural heart disease.